Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study. - Yang P; Pardon LP; Ho AC; Lauer AK; Yoon D; Boye SE; Boye SL; Roman AJ; Wu V; Garafalo AV; Sumaroka A; Swider M; et al. (Lancet (London, England), 2024)